- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Aerovate Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
| 03.12.24 | Aerovate Therapeutics, Inc. - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 12.11.24 | Aerovate Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 31.10.24 | Paragon spinout Jade casts reverse merger spell with Aerovate | 1 | FierceBiotech | ||
| 31.10.24 | Jade, another biotech spinout of Paragon, to merge with Aerovate | 1 | BioPharma Dive | ||
| AEROVATE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 31.10.24 | Jade Biosciences und Aerovate kündigen Fusion an | 1 | Investing.com Deutsch | ||
| 31.10.24 | Jade Biosciences and Aerovate announce merger deal | 8 | Investing.com | ||
| 31.10.24 | Aerovate Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.10.24 | Aerovate climbs on all-stock merger deal with Jade | 1 | Seeking Alpha | ||
| 17.10.24 | Aerovate Therapeutics erfüllt wieder Nasdaq-Anforderungen | 2 | Investing.com Deutsch | ||
| 17.10.24 | Aerovate Therapeutics regains Nasdaq compliance | 1 | Investing.com | ||
| 17.10.24 | Aerovate Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.10.24 | Aerovate Therapeutics announces board member resignation | 1 | Investing.com | ||
| 10.10.24 | Aerovate Therapeutics gibt Rücktritt eines Vorstandsmitglieds bekannt | 9 | Investing.com Deutsch | ||
| 10.10.24 | Aerovate Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.09.24 | Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Update | 1 | MarketBeat | ||
| 12.08.24 | Aerovate Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.07.24 | Aerovate Therapeutics, Inc.: Aerovate Therapeutics to Explore Strategic Alternatives | 325 | GlobeNewswire (Europe) | WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled... ► Artikel lesen | |
| 17.06.24 | Aerovate Therapeutics, Inc.: Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension | 186 | GlobeNewswire (Europe) | WALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension... ► Artikel lesen | |
| 13.05.24 | Aerovate Therapeutics, Inc.: Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights | 425 | GlobeNewswire (Europe) | Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Enrollment continues into the Phase... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 1,890 | +1,94 % | Fast 200 % Kurspotenzial! Nel ASA, Evotec, BioNTech, Medigene Aktien! | Die Aktie von Medigene hat mit dem Turnaround begonnen. Neben positiven Patent-News aus Japan für das Krebs-Testis-Antigen MAGE-A4 treibt eine Kaufempfehlung das Wertpapier. So sehen Analysten mehr... ► Artikel lesen | |
| BB BIOTECH | 40,150 | +0,63 % | BB Biotech: Dividendenvorschlag trotz Herausforderungen im Biotech-Sektor | Die BB Biotech AG blickt auf ein turbulentes Jahr 2024 zurück, das durch die Volatilität des Biotechsektors und eine gedämpfte Anlegerstimmung geprägt war. Trotz negativer Gesamtrendite der Aktie zeigt... ► Artikel lesen | |
| QIAGEN | 43,745 | -1,83 % | Biotech Report: Qiagen behauptet, Evotec leichter | (shareribs.com) Frankfurt 20.01.2025 - Die Biotechnologie-Aktien tendierten im deutschen Handel überwiegend schwächer. Die Marktteilnehmer halten sich zurück, da Trump in den USA seine nächste Amtszeit... ► Artikel lesen | |
| NOVAVAX | 8,689 | -1,05 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| STRYKER | 374,00 | -0,43 % | Jim Cramer on Stryker Corp (SYK): Buy and 'Forget About It' | ||
| ILLUMINA | 129,44 | -0,26 % | Inside the New Illumina MiSeq i100 Series: The Making of the Software | What's it like to build the software in a brand-new sequencer? Illumina's Aneesh Natarajan takes us on the journeyOriginally published on Illumina News Center NORTHAMPTON, MA / ACCESS Newswire / January... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,400 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results | -CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized... ► Artikel lesen | |
| AAP IMPLANTATE | 1,880 | 0,00 % | EQS-News: aap Implantate AG: Deutliche Fortschritte in allen operativen Bereichen; stabiles viertes Quartal führt zu 12.2 Mio. EUR Jahres-Umsatz (+6%) | EQS-News: aap Implantate AG
/ Schlagwort(e): Vertriebsergebnis
Deutliche Fortschritte in allen operativen Bereichen; stabiles viertes Quartal führt zu 12.2 Mio. EUR Jahres-Umsatz... ► Artikel lesen | |
| OCUGEN | 0,749 | +0,94 % | Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200-a Novel Integrin-Targeting Biologic for Diabetic Macular Edema | MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 1,140 | +2,67 % | Truist Financial Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $5.00 | ||
| INTELLIA THERAPEUTICS | 10,735 | +2,63 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| SCORPIUS | 0,274 | +7,03 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer | DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| EDITAS MEDICINE | 1,338 | +2,10 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,300 | +0,36 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) | -ORLADEYO net revenue expected to be between $515-$535 million in 2025- -Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025- -Company achieved operating profit in... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,574 | +3,61 % | Defence Therapeutics Inc.: Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 | Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals... ► Artikel lesen |
AEROVATE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,030 (+1,17 %) liegt der Kurs bei 2,590 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AEROVATE THERAPEUTICS INC finden Sie auf Wallstreet Online.
